It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness including deafness caused by a mutation of the gene encoding for Otoferlin, and hearing loss related to mutation in GJB2 gene to potentially address important hearing loss segments in adults and children. Sensorion has entered into a broad strategic collaboration with Institut Pasteur focused on the genetics of hearing. Its clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 Proof of Concept study of SENS-401 clinical study in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, a study of SENS-401 in patients scheduled for cochlear implantation. Its portfolio combines both small molecule programs and a preclinical portfolio of inner ear gene therapies. Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and modalities for drug candidates. Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need. The agenda of the conference can be found here.

She will also give a talk on ' Gene Therapies for Treating Monogenic Hearing Disorders' on June 23, 2022. Nora Yang, Ph.D, SensorionвЂ™s Chief Scientific Officer, who will also participate in the same event, will take part in a panel discussion entitled ' De-Risking the Early Development Process - a robust and comprehensive early development process is essential to minimize setbacks faced in the clinic' on June 21, 2022.

GГ©raldine Honnet, M.D., SensorionвЂ™s Chief Medical Officer, will give a talk on ' AUDIBLE-S, A Study to Evaluate the Use of SENS-401 in SSNHL Disease: Results & Lessons Learned' on June 22, 2022, at the 2nd Inner Ear Disorder Therapeutics Summit, being held in Boston, USA, 20-23 June 2022. Sensorion (Paris:ALSEN) (FR0012596468 вЂ“ ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, is pleased to announce the participation in-person of members of SensorionвЂ™s senior management in the Inner Ear Disorder Therapeutics Summit, a scientific conference being held in Boston, USA, in June 2022. MONTPELLIER, France, June 15, 2022-( BUSINESS WIRE)-Regulatory News:

Yahoo ifinance ions